Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, shares the results of an investigation into the optimal chemotherapy regimen for NUT carcinoma. An international registry of patients with NUT carcinoma was used to examine the most effective chemotherapies. As pediatric literature supports ifosfamide-based chemotherapies for the cancer, the investigation identified patients who had complete results to ifosfamide or platinum-based treatment, patients with non-metastatic disease, and patients with metastatic disease. The study demonstrated that there was a signal for benefit for ifosfamide chemotherapy in non-metastatic patients and improvements were observed in objective response rates and progression-free survival. Dr Luo concludes that ifosfamide treatment should be used with caution and is not recommended for metastatic NUT carcinoma. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
